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Abstract
Background and objectives. Patients with rheumatoid arthritis (RA) frequently suﬀer from
muscle weakness. Oral administration of creatine has been shown to improve muscle strength
in healthy subjects. The objective of this study was to examine the eﬀect of oral creatine
supplementation on muscle weakness, disease activity and activities of daily living in patients
with RA.
Methods. During a period of 3 weeks, 12 patients with RA were treated with creatine
monohydrate (20 g/day for 5 days followed by 2 g/day for 16 days). They were examined on
entry and at the end of the study. The patients were investigated clinically, blood and urine
samples were obtained, muscle biopsies were performed before and after treatment, muscle
strength was determined, and self-administered patient questionnaires were completed.
Results. From all patients we were able to obtain full clinical and questionnaire data, while
biopsies were taken from 12 patients at the start and from nine patients at the end of the
study. Muscle strength, as determined by the muscle strength index, increased in eight of 12
patients. In contrast, physical functional ability and disease activity did not change
significantly. The creatine concentration in serum and skeletal muscle increased significantly,
while creatine phosphate and total creatine did not increase in skeletal muscle. The skeletal
muscle creatine content was associated with muscle strength at baseline but not after
administration of creatine. The changes in muscle strength were not associated with the
changes in skeletal muscle creatine or creatine phosphate.
Conclusion. Although the skeletal muscle creatine content and muscle strength increased
with creatine administration in some patients with RA, a clear clinical benefit could not be
demonstrated for this treatment when the patients were considered as one group.
K : Creatine kinase, Creatine supplementation, Muscle strength, Rheumatoid arthritis.
The importance of muscle weakness in the disability of activity has been found to be associated with muscle
weakness, suggesting that alterations in creatine meta-patients with rheumatoid arthritis (RA) has long been
bolism may be involved [9]. Similar to patients withrecognized [1–5]. Muscle weakness is generally attrib-
RA, patients with gyrate atrophy also have type 2uted to a reflex response to pain, joint deformation or
muscle fibre atrophy [10]. In this group of patients, thisdisuse, extra-articular manifestations of the disease
change in muscle fibre composition is associated with aand/or psychological factors. In comparison, muscle
decrease in the skeletal muscle creatine content whichinflammation with an increase in serum creatine kinase
can be corrected by the administration of creatine.(CK) activity and specific histological changes are rare
In healthy persons and patients with chronic heartin patients with RA [6, 7].
failure, oral administration of high doses of creatineMore commonly, muscle weakness in RA is accom-
increased the skeletal muscle creatine and phosphocreat-panied by normal or low serum CK activity, lack of
ine content in most but not all subjects [11–16 ]. Thisabnormalities in electromyographic examination and
increase was generally associated with an increase innon-specific type 2 fibre atrophy [7, 8]. Low serum CK
short-term exercise capacity [13, 15–18], but had no
beneficial eﬀect on aerobic exercise capacity [19, 20].
On the basis of these studies, we hypothesized thatSubmitted 23 March 1999; revised version accepted 7 October 1999.
Correspondence to: G. Stucki. the administration of creatine may improve the skeletal
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muscle function of patients with RA. We therefore DAS, only 28 and not 68 joints are examined, reducing
the burden for the patients without being less accurateinvestigated the eﬀects of long-term oral administration
of creatine on physical performance and skeletal muscle [25].
Creatine in serum, urine and skeletal muscle wascreatine metabolism of patients with RA.
determined spectrophotometrically according to Bernt
et al. [26 ]. Creatine phosphate in skeletal muscleMaterials and methods
was determined spectrophotometrically according to
Lamprecht et al. [27]. The coeﬃcient of variation of theDesign
technique that was used to measure the muscle creatineThe study was a 3-week open study of creatine
and muscle creatine phosphate levels is below 5%. Thesupplementation in 12 RA patients fulfilling the
muscle creatine content is expressed per g tissue wetAmerican College of Rheumatology (ACR) criteria for
weight. Laboratory assessment also included the ESRRA [21]. It was reviewed and accepted by the Ethics
and serum CK activity which were determined by routineCommittee of the Medical Faculty of the University
methods of clinical chemistry.of Zurich.
Analyses and sample sizeIntervention
The diﬀerences between the values before and afterA 3-week supplementation with creatine monohydrate
treatment were tested by a one-sample t-test. The levelchewing tablets ( Wander Pharma, Bern, Switzerland)
of significance was set to 0.05. The sample size calcula-was given. We administered 20 g/day (four times 5 g)
tion was based on a one-sided paired t-test (pre- andfor the first 5 days ( loading phase) and 2 g/day (four
post-medication strength constitute the matched pairs).times 0.5 g) for the remaining 16 days (maintenance
We calculated that 11 pairs of before and after measure-phase). This dosage was based on creatine supple-
ments would be needed to detect an improvement of atmentation in clinical [13] and experimental studies [11,
least 20% (the assumed minimal diﬀerence of clinical12, 14], in which no side-eﬀects associated with this
importance) with a power of 90% given that such aintervention were reported. According to the protocol,
diﬀerence actually exists.patients were asked not to change their habits and
The primary outcome variable tested was the MSI.physical activity during the study.
To examine whether the expected increase in isometric
Data collection muscle strength would translate into statistically signifi-
cant and clinically meaningful gains in physical func-All participants were examined on entry and at the end
tional ability, we also examined for changes in the HAQof the study. These investigations included the collection
score. Unless stated otherwise, data are presented asof a blood sample and 24-h urine, a clinical examination,
mean± ..a muscle biopsy (quadriceps) and muscle strength meas-
urements (elbow and knee). In addition, the participants
had to complete self-administered questionnaires. Results
Measures Patients
While isokinetic measurements have been used in studies We obtained full clinical and questionnaire data from
by Greenhaﬀ et al. [17], this type of exercise caused all patients. However, skeletal muscle biopsy was pos-
pain to patients with RA in pre-testing. We thus used sible in 12 patients at the start of the study but in only
isometric muscle strength measurements in the form of nine patients at the end (three patients refused a second
a muscle strength index (MSI) which has been validated biopsy). The mean age of the study population was
in patients with RA. The MSI includes measurements 54 yr (..= 13), with a range of 28–70 yr. Seventy-five
of knee and elbow extension and flexion. To reduce the per cent of patients were female. The mean weight was
burden of measurements we restricted the measurements 68 kg (..= 4) and the mean height was 166 cm
to the left side of the body (the resulting index is of (..= 3). The medium duration of disease was 9 yr
virtually identical reliability as compared with the test (range 1–26 yr). The rheumatoid factor was positive in
assessing both sides) [5]. 11 of 12 patients.
To examine physical functional disability we used the
Side-eﬀects and complianceHealth Assessment Questionnaire (HAQ) [22, 23], one
of the most frequently used instruments for measuring During the study period, patients reported no adverse
functional disability and daily activities in patients with events associated with the ingestion of creatine. All
RA. The HAQ measures the capabilities in dressing, patients maintained creatine supplementation during the
arising, walking, hygiene, reaching, gripping, and other whole study period, as assessed by tablet counting and
activities. The questionnaire is self-administered and determination of creatine concentrations in serum and
takes less than 5 min to complete. urine (see below).
To control for disease activity we used the disease
Muscle strength and physical functional abilityactivity score (DAS) which is calculated based on
the number of swollen and tender joint counts and the Muscle strength as measured by the MSI showed an
increase in eight of 12 patients and reached statisticalerythrocyte sedimentation rate (ESR) [24]. For the
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Creatine metabolism
As shown in Table 1 and Fig. 2, the skeletal muscle
creatine content increased in eight of the nine patients
studied with creatine administration (P= 0.04). In con-
trast, the skeletal muscle content of creatine phosphate
as well as the total creatine content did not change
significantly. The serum creatine concentration and the
urinary excretion of creatine increased by a factor of 4
and 30, respectively, with creatine supplementation,
suggesting that the patients were compliant. Urinary
excretion of creatine at the end of the study was 2 g/day,
accounting for 100% of the dose ingested. The serum
activity of CK did not change with creatine
administration.
Association between creatine metabolism and muscle
strength
Cross-sectionally, the skeletal muscle creatine content
was associated with the MSI at baseline (r= 0.55,
P= 0.06), but not after treatment with creatine (r=
0.03). Instead, neither the phosphocreatine nor the total
creatine content were associated with the MSI at both
time points. Longitudinally, the changes in the MSI
following creatine administration were not associated
with any of the creatine parameters. Interestingly, the
F. 1. MSI before and after treatment with creatine. The total creatine content increased in three of the four
MSI increased in eight 12 patients, reaching statistical signifi- patients with the lowest starting value, and all of these
cance (P= 0.02). patients showed a concomitant increase in muscle
strength.
significance (Table 1 and Fig. 1). Concerning individual Discussion
joints, muscle strength increased for the index (mean
diﬀerence= 7.4 percentage units, ..= 2.85, P< 0.02) Our study illustrates that patients with RA can be
treated safely with high doses of creatine. Regarding alland for the flexion of elbow and knee, but was not
significant for the extension of elbow and knee patients as one group, this treatment is associated with
an increase in muscle strength but not in the skeletal(P= 0.08). The MSI was associated with physical func-
tional ability as measured with the HAQ both at baseline muscle creatine content.
The skeletal muscle creatine content in the patients(r= −0.71, P= 0.01) and after treatment with creatine
(r= −0.62, P= 0.03). However, physical functional studied was 23 mmol/g wet weight, which corresponds
to approximately 115 mmol/g dry weight, assuming adisability (HOQ) did not change significantly with the
administration of creatine, whereas disease activity as water content of 80% [28]. This value agrees well with
the 110–140 mmol/g dry weight reported in studies withmeasured with the DAS showed a significant decrease.
T 1. Clinical and biomedical characterization of the patients studied (n= 12). Muscle biopsies could only be obtained from nine patients
at follow-up. Data are given as mean (..)
Measure Baseline Follow-up Change P-value
Clinical assessment
MSI 53.2 (9.1) 60.6 (9.0) 7.4 (2.9) 0.02
HAQ 1.20 (0.16) 1.24 (0.17) 0.06 (0.06) 0.38
DAS 4.35 (0.36) 3.68 (0.32) −0.67 (0.24) 0.02
Skeletal muscle
Creatine (mmol/g) 6.9 (0.7) 7.4 (1.0) 1.4 (0.6) 0.04
Creatine phosphate (mmol/g) 16.2 (0.9) 12.3 (1.5) −3.0 (2.2) 0.21
Total creatine (mmol/g) 23.0 (1.3) 19.7 (2.19) −1.60 (2.55) 0.54
Serum
Creatine (mmol/l ) 36.5 (5.9) 153 (23) 116 (22) <0.01
CK (U/l ) 66 (6) 73 (18) 7 (16) 0.29
Urine
Creatine (mmol/24 h) 450 (200) 13 900 (1300) 13 450 (1240) <0.01
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F. 2. Creatine content in skeletal muscle before and after treatment with creatine. The creatine content increased in eight of
nine patients with treatment ( left), whereas the total creatine content (creatine and phosphocreatine) showed no significant
change (right).
normal subjects [11–14], suggesting that the skeletal Creatine supplementation has been shown to be asso-
ciated with increased muscle strength during short-termmuscle creatine metabolism is not disturbed profoundly
in patients with RA. Treatment with creatine led to an exercise in normal subjects [15–18] and in patients with
chronic heart disease [13]. On the other hand, no eﬀectincrease in the skeletal muscle creatine content in eight
of the nine patients, whereas creatine phosphate and the of creatine supplementation could be demonstrated in
normal subjects performing long-term exercise [19, 20].total creatine content did not change significantly. In
normal subjects, similar treatments were associated with These findings are in agreement with the physiological
role of the creatine/creatine phosphate system, whicha 10–20% increase in the total skeletal muscle creatine
content in most [11, 13–15] but not all subjects studied provides energy for less than a minute in a maximally
working skeletal muscle [29]. The MSI used in the[12]. Since poor compliance and technical problems in
the quantification of creatine are unlikely to be the current studies is calculated from the maximal force
achieved by diﬀerent muscle groups during isometricreasons for our findings, the exact causes for the lack
of increase in the skeletal muscle creatine content in contraction over a short time. This type of muscle
contraction corresponds to short-term exercise andpatients with RA remain unclear. As indicated by the
urinary excretion of creatine, which equalled the dose could therefore potentially be aﬀected by the skeletal
muscle creatine content. Indeed, administration of creat-administered, reduced absorption of creatine can be
excluded. The most probable reasons for our findings ine was associated with an increase in the MSI in eight
of 12 patients, reaching statistical significance. Thisinclude, therefore, alterations in the kinetics of creatine
in patients with RA, for instance altered distribution increase cannot be explained by changes in the skeletal
muscle creatine content, however, since there was no(e.g. reduced transport into skeletal muscle), increased
metabolism and/or increased excretion. Since our study association between these two variables and the skeletal
muscle total creatine content did not increase. On thewas not designed to answer these questions, further
studies are necessary to investigate in more detail creat- other hand, there was a significant association between
the skeletal muscle total creatine content and muscleine metabolism in patients with RA.
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